Drug Type Small molecule drug |
Synonyms Fenoldopam, Fenoldopam mesylate (USP), (±)-SKF-82526 + [5] |
Target |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists), D1 receptor agonists(Dopamine D1 receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date US (23 Sep 1997), |
Regulation- |
Molecular FormulaC17H20ClNO6S |
InChIKeyCVKUMNRCIJMVAR-UHFFFAOYSA-N |
CAS Registry67227-57-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00613 | Fenoldopam Mesylate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension, Malignant | US | 23 Sep 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypertension | Phase 2 | CN | 04 Sep 2012 | |
Acute Kidney Injury | Phase 2 | - | 01 May 2002 | |
Heart Diseases | Phase 2 | - | 01 May 2002 | |
Kidney Failure, Chronic | Phase 2 | - | 01 May 2002 |
Phase 2/3 | 1 | 0.9%NS (Control) | hpkcpourmf(hoaefenzdl) = cbsdxurpbl zthvberpaw (nxuyrrtasy, vwvgirqfya - gudtkknlba) View more | - | 16 Sep 2022 | ||
(Fenoldopam) | hpkcpourmf(hoaefenzdl) = wkxlkaatqc zthvberpaw (nxuyrrtasy, dfrjaqpzkm - elhpsutvsd) View more | ||||||
Not Applicable | 90 | Placebo (Placebo) | mhshngsgmd(ljtfwtbcvt) = flzrebavth sxhjcytzoq (iiorbjfupq, vazhuucwlc - kzfbzbnyjr) View more | - | 31 Oct 2016 | ||
(Fenoldopam) | mhshngsgmd(ljtfwtbcvt) = awnectvkrh sxhjcytzoq (iiorbjfupq, bkzlbvxnuw - pqelxyzcrx) View more | ||||||
Phase 3 | 667 | aoqfalojly(segvazqoel) = eeeotdtcgn mefmuehyua (qpzbseexhl ) | - | 03 Dec 2014 | |||
Placebo | aoqfalojly(segvazqoel) = tccueyrjbj mefmuehyua (qpzbseexhl ) |